Amino.Desk

Vilon (Lys-Glu)

Updated Nov 17, 2026 · Clinical review: pending

Vilon is one of the Russian short peptides sold as bioregulators. It is marketed for immune support and anti-aging. The evidence comes almost entirely from the group that developed it, and no independent trial has tested it in people.

What it is

Vilon is a peptide of two amino acids, lysine and glutamic acid. It was identified from the thymus extract Thymalin.

It belongs to a family of peptides, two to four amino acids long, developed in St. Petersburg by Vladimir Khavinson's group. The idea behind them is that each organ makes its own short regulatory peptides, and that supplying them restores that organ. The group developed each target in two forms, a tissue extract and a short synthetic peptide. The synthetic ones are what research suppliers sell.

What the evidence shows

The developers reported that Vilon slowed tumor growth and extended lifespan in mice, and their reviews describe use in older patients. One independent assessment calls it the weakest-evidenced peptide in the family, because no outside laboratory has reproduced any of the findings.

For the family as a whole, the record is cell experiments, rodent studies, and small, often unblinded human studies run by the original group. Key findings have not been reproduced by independent teams. The most-cited human study, a 266-person cohort followed for six to eight years, tested thymus and pineal extracts, not this peptide, and was not blinded.

Legal status

Reported dosing

We do not publish a protocol for this compound.

No dose has been established in a controlled human trial. The course schedules that circulate come from the developers' own tradition and from sellers.

Safety

Common questions

What is Vilon?

A Russian short peptide, one of the Khavinson bioregulators, sold for immune support and anti-aging.

Is Vilon FDA-approved?

No. It is not approved and is not eligible for pharmacy compounding.

Has Vilon been tested in people?

The developers describe clinical use in older patients. No independent or registered trial has tested it.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy